

Isabel T Rubio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7197944/publications.pdf>

Version: 2024-02-01

138
papers

7,533
citations

109321

35
h-index

56724

83
g-index

152
all docs

152
docs citations

152
times ranked

9102
citing authors

#	ARTICLE	IF	CITATIONS
1	70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 717-729.	27.0	1,427
2	Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2019, 30, 1194-1220.	1.2	1,241
3	PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition. <i>Cancer Discovery</i> , 2012, 2, 1036-1047.	9.4	507
4	Subareolar Versus Peritumoral Injection for Location of the Sentinel Lymph Node. <i>Annals of Surgery</i> , 1999, 229, 860.	4.2	304
5	RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. <i>Annals of Oncology</i> , 2018, 29, 1203-1210.	1.2	280
6	Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. <i>Annals of Oncology</i> , 2018, 29, 405-417.	1.2	246
7	70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. <i>Lancet Oncology</i> , The, 2021, 22, 476-488.	10.7	179
8	A <scp>RAD</scp> 51 assay feasible in routine tumor samples calls <scp>PARP</scp> inhibitor response beyond <scp>BRCA</scp> mutation. <i>EMBO Molecular Medicine</i> , 2018, 10, .	6.9	169
9	Use of touch preps for intraoperative diagnosis of sentinel lymph node metastases in breast cancer. <i>Annals of Surgical Oncology</i> , 1998, 5, 689-694.	1.5	157
10	The cancer stem-cell signaling network and resistance to therapy. <i>Cancer Treatment Reviews</i> , 2016, 49, 25-36.	7.7	122
11	The requirements of a specialist breast centre. <i>Breast</i> , 2020, 51, 65-84.	2.2	111
12	The superparamagnetic iron oxide is equivalent to the Tc99 radiotracer method for identifying the sentinel lymph node in breast cancer. <i>European Journal of Surgical Oncology</i> , 2015, 41, 46-51.	1.0	104
13	Intraoperative molecular analysis of total tumor load in sentinel lymph node: a new predictor of axillary status in early breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 87-93.	2.5	101
14	Intraoperative Ultrasound-Guided Excision of Axillary Clip in Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Therapy (ILINA Trial). <i>Annals of Surgical Oncology</i> , 2018, 25, 784-791.	1.5	101
15	Sentinel lymph node biopsy for staging breast cancer. <i>American Journal of Surgery</i> , 1998, 176, 532-537.	1.8	98
16	Intraoperative ultrasound-guided breast biopsy. <i>American Journal of Surgery</i> , 2000, 180, 419-423.	1.8	90
17	Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Rationale for the EUBREAST-03 AXSANA Study. <i>Cancers</i> , 2021, 13, 1565.	3.7	85
18	Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 523-537.	2.5	84

#	ARTICLE	IF	CITATIONS
19	Intraoperative touch preparation for sentinel lymph node biopsy: A 4-year experience. <i>Annals of Surgical Oncology</i> , 2002, 9, 333-339.	1.5	82
20	Impact of multicentricity on clinical outcome in patients with T1-2, N0-1, M0 breast cancer. <i>Annals of Surgical Oncology</i> , 2000, 7, 581-587.	1.5	75
21	p95HER2â€T cell bispecific antibody for breast cancer treatment. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	59
22	Breast-conserving surgery following neoadjuvant therapy-a systematic review on surgical outcomes. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 1-12.	2.5	55
23	Prediction of non-sentinel lymph node metastasis in early breast cancer by assessing total tumoral load in the sentinel lymph node by molecular assay. <i>European Journal of Surgical Oncology</i> , 2013, 39, 766-773.	1.0	50
24	Intraoperative Ultrasound-Guided Lumpectomy Versus Mammographic Wire Localization for Breast Cancer Patients After Neoadjuvant Treatment. <i>Annals of Surgical Oncology</i> , 2016, 23, 38-43.	1.5	50
25	Effect of Glutamine on Methotrexate Efficacy and Toxicity. <i>Annals of Surgery</i> , 1998, 227, 772-780.	4.2	50
26	Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. <i>Lancet Oncology</i> , The, 2021, 22, e18-e28.	10.7	49
27	Surgical treatment of nonpalpable primary invasive and in situ breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 645-663.	27.6	47
28	Role of Specimen Radiography in Patients Treated With Skin-Sparing Mastectomy for Ductal Carcinoma In Situ of the Breast. <i>Annals of Surgical Oncology</i> , 2000, 7, 544-548.	1.5	46
29	Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies. <i>PLoS ONE</i> , 2015, 10, e0129876.	2.5	45
30	Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement. <i>Oncologist</i> , 2019, 24, 603-611.	3.7	43
31	Nomogram including the total tumoral load in the sentinel nodes assessed by one-step nucleic acid amplification as a new factor for predicting nonsentinel lymph node metastasis in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 371-380.	2.5	40
32	Gene expressionâ€based classifications of fibroadenomas and phyllodes tumours of the breast. <i>Molecular Oncology</i> , 2015, 9, 1081-1090.	4.6	39
33	Risk factors for locoregional disease recurrence after breastâ€conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient metaâ€analysis. <i>Cancer</i> , 2018, 124, 2923-2930.	4.1	39
34	Intraoperative localization after stereotactic breast biopsy without a needle. <i>American Journal of Surgery</i> , 2001, 182, 584-589.	1.8	37
35	Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	36
36	Intraoperative Assessment of Sentinel Lymph Nodes After Neoadjuvant Chemotherapy in Patients with Breast Cancer. <i>Annals of Surgical Oncology</i> , 2010, 17, 235-239.	1.5	35

#	ARTICLE	IF	CITATIONS
37	Role of total tumour load of sentinel lymph node on survival in early breast cancer patients. <i>Breast</i> , 2017, 33, 8-13.	2.2	34
38	Boosting the tumor bed from deep-seated tumors in early-stage breast cancer: A planning study between electron, photon, and proton beams. <i>Radiotherapy and Oncology</i> , 2010, 96, 192-198.	0.6	33
39	Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. <i>Annals of Oncology</i> , 2013, 24, 1980-1985.	1.2	32
40	Effect of Cellular Senescence on the Growth of HER2-Positive Breast Cancers. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv020-djv020.	6.3	32
41	Electrothermal bipolar vessel sealing system in axillary dissection: A prospective randomized clinical study. <i>International Journal of Surgery</i> , 2011, 9, 636-640.	2.7	31
42	Extensive nodal involvement increases the positivity of blue nodes in the axillary reverse mapping procedure in patients with breast cancer. <i>Journal of Surgical Oncology</i> , 2012, 106, 89-93.	1.7	29
43	Different Prognostic Implications of Residual Disease After Neoadjuvant Treatment: Impact of Ki 67 and Site of Response. <i>Annals of Surgical Oncology</i> , 2016, 23, 3831-3837.	1.5	29
44	Sentinel lymph node biopsy after neoadjuvant treatment in breast cancer: Work in progress. <i>European Journal of Surgical Oncology</i> , 2016, 42, 326-332.	1.0	25
45	EUSOMA position regarding breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and the use of textured implants. <i>Breast</i> , 2019, 44, 90-93.	2.2	25
46	Can we predict local recurrence in breast conserving surgery after neoadjuvant chemotherapy?. <i>European Journal of Surgical Oncology</i> , 2010, 36, 528-534.	1.0	23
47	Multidisciplinary approach to breast cancer diagnosed during pregnancy: Maternal and neonatal outcomes. <i>Breast</i> , 2013, 22, 515-519.	2.2	22
48	Variability in breast cancer surgery training across Europe: An ESSO-EUSOMA international survey. <i>European Journal of Surgical Oncology</i> , 2019, 45, 567-572.	1.0	22
49	A randomized study comparing different doses of superparamagnetic iron oxide tracer for sentinel lymph node biopsy in breast cancer: The SUNRISE study. <i>European Journal of Surgical Oncology</i> , 2020, 46, 2195-2201.	1.0	22
50	Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy. <i>Breast</i> , 2022, 63, 123-139.	2.2	22
51	Axillary surgery after neoadjuvant therapy in initially node-positive breast cancer: international EUBREAST survey. <i>British Journal of Surgery</i> , 2022, 109, 857-863.	0.3	22
52	Surgical use of breast ultrasound. <i>Surgical Clinics of North America</i> , 2003, 83, 771-788.	1.5	21
53	Pregnancy after treatment of breast cancer in young women does not adversely affect the prognosis. <i>Breast</i> , 2012, 21, 272-275.	2.2	21
54	Oral Glutamine Reduces Radiation Morbidity in Breast Conservation Surgery. <i>Journal of Parenteral and Enteral Nutrition</i> , 2013, 37, 623-630.	2.6	21

#	ARTICLE	IF	CITATIONS
55	Surgery improves survival in elderly with breast cancer. A study of 465 patients in a single institution. <i>European Journal of Surgical Oncology</i> , 2015, 41, 635-640.	1.0	20
56	Margins in breast conserving surgery: A practice-changing process. <i>European Journal of Surgical Oncology</i> , 2016, 42, 631-640.	1.0	20
57	Abstract S6-05: Characterization of male breast cancer: First results of the EORTC10085/TBCRC/BIG/NABCG International Male BC Program. , 2015, , .		20
58	Techniques of sentinel lymph node biopsy. <i>Journal of Surgical Oncology</i> , 2001, 20, 214-223.	1.4	18
59	Breast conservative surgery after neoadjuvant chemotherapy in breast cancer patients: Comparison of two tumor localization methods. <i>European Journal of Surgical Oncology</i> , 2011, 37, 1038-1043.	1.0	17
60	Changes in Breast Cancer Reports after Pathology Second Opinion. <i>Breast Journal</i> , 2014, 20, 295-301.	1.0	17
61	Intraoperative assessment of sentinel lymph node by one-step nucleic acid amplification in breast cancer patients after neoadjuvant treatment reduces the need for a second surgery for axillary lymph node dissection. <i>Breast</i> , 2017, 31, 40-45.	2.2	16
62	Percutaneous ultrasound-guided vacuum-assisted excision of benign breast lesions: A learning curve to assess outcomes. <i>British Journal of Radiology</i> , 2019, 92, 20180626.	2.2	16
63	Abstract CT039: Primary analysis of the EORTC 10041/ BIG 3-04 MINDACT study: a prospective, randomized study evaluating the clinical utility of the 70-gene signature (MammaPrint) combined with common clinical-pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes. , 2016, . . .		16
64	Learning curves in intraoperative ultrasound guided surgery in breast cancer based on complete breast cancer excision and no need for second surgeries. <i>European Journal of Surgical Oncology</i> , 2019, 45, 578-583.	1.0	15
65	Racial Differences in Breast Cancer Survival: The Effect of Residual Disease. <i>Journal of Surgical Research</i> , 2001, 100, 161-165.	1.6	14
66	Global Forum of Cancer Surgeons: Declaration of Intent. <i>Annals of Surgical Oncology</i> , 2017, 24, 2429-2431.	1.5	13
67	Surgery improves breast cancer-specific survival in octogenarians with early-stage breast cancer. <i>International Journal of Surgery</i> , 2013, 11, 554-557.	2.7	12
68	Detection of sentinel lymph node in breast cancer recurrence may change adjuvant treatment decision in patients with breast cancer recurrence and previous axillary surgery. <i>Breast</i> , 2014, 23, 460-465.	2.2	12
69	Theoretical and practical knowledge curriculum for European Breast Surgeons. <i>European Journal of Surgical Oncology</i> , 2020, 46, 717-736.	1.0	12
70	Lymphatic mapping could not be impaired in the presence of breast carcinoma and coexisting small lymphocytic lymphoma. <i>American Journal of Case Reports</i> , 2013, 14, 322-325.	0.8	12
71	Leveraging the increased rates of pathologic complete response after neoadjuvant treatment in breast cancer to de-escalate surgical treatments. <i>Journal of Surgical Oncology</i> , 2021, 123, 71-79.	1.7	11
72	Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1186-1197.	1.6	10

#	ARTICLE	IF	CITATIONS
73	Management of the axilla in early breast cancer patients in the genomic era. <i>Annals of Oncology</i> , 2013, 24, 1163-1170.	1.2	9
74	Breast-Conservative Surgery Followed by Radiofrequency Ablation of Margins Decreases the Need for a Second Surgical Procedure for Close or Positive Margins. <i>Clinical Breast Cancer</i> , 2014, 14, 346-351.	2.4	9
75	Sentinel lymph node metastasis after neoadjuvant treatment in breast cancer: Any size matters?. <i>World Journal of Clinical Oncology</i> , 2015, 6, 202.	2.3	9
76	A European, Observational Study of Endocrine Therapy Administration in Patients With an Initial Diagnosis of Hormone Receptor-Positive Advanced Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, e613-e619.	2.4	9
77	ASO Author Reflections: Moving Forward De-escalation of Axillary Surgery After Neoadjuvant Treatment in Breast Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 638-639.	1.5	9
78	Should breast reconstruction and breast oncoplastic procedures be performed during the coronavirus pandemic?. <i>Ecanermedalscience</i> , 2020, 14, 1041.	1.1	9
79	Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. <i>Npj Breast Cancer</i> , 2021, 7, 145.	5.2	9
80	Breast conservative surgery in breast cancer: Simple can be harder than complex. <i>Journal of Surgical Oncology</i> , 2014, 110, 1-1.	1.7	8
81	Perspectives on preoperative systemic treatment and breast conservative surgery: One step forward or two steps back?. <i>Breast</i> , 2018, 41, 133-135.	2.2	8
82	Breast and axillary surgery in malignant breast disease: a review focused on literature of 2018 and 2019. <i>Current Opinion in Obstetrics and Gynecology</i> , 2020, 32, 91-99.	2.0	8
83	Factors affecting surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. <i>Annals of Oncology</i> , 2014, 25, 910-911.	1.2	7
84	Intraoperative ultrasound guided breast surgery: paving the way for personalized surgery. <i>Gland Surgery</i> , 2016, 5, 366-368.	1.1	7
85	Education and Training in Breast Cancer Surgery in Europe. <i>Breast Care</i> , 2019, 14, 366-372.	1.4	7
86	Intraoperative Touch Preparation for Sentinel Lymph Node Biopsy: A 4-Year Experience. <i>Annals of Surgical Oncology</i> , 2002, 9, 333-339.	1.5	6
87	The ESSO core curriculum committee update on surgical oncology. <i>European Journal of Surgical Oncology</i> , 2021, 47, e1-e30.	1.0	6
88	Four-fraction ultra-accelerated minimal breast irradiation in early breast cancer: The initial feasibility results of an institutional experience. <i>Brachytherapy</i> , 2022, 21, 475-486.	0.5	6
89	Breast Metastasis from Rhabdomyosarcoma of the Nasal Septum in a Pregnant Adult Woman. <i>Breast Journal</i> , 2011, 17, 420-421.	1.0	4
90	European Guidelines on the Organisation of Breast Centres and Voluntary Certification Processes. <i>Breast Care</i> , 2019, 14, 359-365.	1.4	4

#	ARTICLE	IF	CITATIONS
91	Axillary staging based on molecular analysis: Results of the B-CLOSER-II study. <i>Pathology Research and Practice</i> , 2020, 216, 153197.	2.3	4
92	Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 98.	5.2	4
93	Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts. <i>Oncotarget</i> , 2016, 7, 67956-67965.	1.8	4
94	Removal of all radioactive sentinel nodes in breast cancer improves the detection of positive sentinel nodes. <i>Clinical and Translational Oncology</i> , 2008, 10, 347-350.	2.4	3
95	Clinical utility of Axillary Reverse Mapping (ARM) in an era of changing perceptions concerning axillary surgery. <i>European Journal of Surgical Oncology</i> , 2016, 42, 585-587.	1.0	3
96	Breast implant associated anaplastic large cell lymphoma: Impact and implications. <i>European Journal of Surgical Oncology</i> , 2017, 43, 1383-1384.	1.0	3
97	Abstract P1-09-09: Efficacy and gene expression results from SOLT11007 NEOERIBULIN phase II clinical trial in HER2-negative early breast cancer. , 2017, , .		3
98	Increased detection of sentinel nodes in breast cancer patients with the use of superparamagnetic iron oxide tracer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 100-100.	1.6	3
99	Standard anthracycline-based vs. docetaxel-capecitabine in early breast cancer: Results from the chemotherapy randomization (R-C) of EORTC 10041/ BIG 3-04 MINDACT phase III trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 516-516.	1.6	3
100	Minimally invasive tumor bed implant (MITBI) and peri-operative high-dose-rate brachytherapy (PHDRBT) for accelerated minimal breast irradiation (AMBI) or anticipated boost (A-PHDRBT-boost) in breast-conserving surgery for ductal carcinoma in situ. <i>Journal of Contemporary Brachytherapy</i> , 2020, 12, 521-532.	0.9	3
101	Health-Related Quality of Life After Nipple-Sparing Mastectomy: Results From the INSPIRE Registry. <i>Annals of Surgical Oncology</i> , 2022, 29, 1722-1734.	1.5	3
102	Neoadjuvant approach in patients with early breast cancer: patient assessment, staging, and planning. <i>Breast</i> , 2021, , .	2.2	3
103	Positive sentinel lymph node: New controversies regarding axillary node dissection. <i>Journal of Surgical Oncology</i> , 2006, 93, 517-518.	1.7	2
104	Transforming Breast Cancer Together: European elections manifesto 2019 seizing the opportunities for breast cancer patients. <i>Breast</i> , 2019, 48, 54-57.	2.2	2
105	European Society of Surgical Oncology's strategy for clinical research: Paving the way for a culture of research in cancer surgery. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1515-1519.	1.0	2
106	About the French prohibition of textured breast implants: is it justified or over-cautious? The EUSOMA, ESSO/BRESSO position. <i>Breast</i> , 2019, 46, 95-96.	2.2	2
107	Local Treatment of Triple-Negative Breast Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 32-40.	2.0	2
108	The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers. <i>Npj Breast Cancer</i> , 2021, 7, 73.	5.2	2

#	ARTICLE	IF	CITATIONS
109	Prognostic and therapeutic implications of fibroblast growth factor receptors (FGFRs) 1 and 2 gene amplifications in patients (pts) with advanced breast cancer (ABC).. Journal of Clinical Oncology, 2016, 34, 537-537.	1.6	2
110	The Discrepancy Between High Pathological Complete Response (PCR) Rate and Low Breast Conserving Surgery (BCS) Following Neoadjuvant Therapy: Analysis from the Neoalto Trial (BIG 1-06). Annals of Oncology, 2012, 23, ix4.	1.2	1
111	Re: Time to Adjuvant Chemotherapy for Breast Cancer in National Comprehensive Cancer Network Institutions. Journal of the National Cancer Institute, 2013, 105, 1912-1912.	6.3	1
112	A gap analysis of opportunities and priorities for breast surgical research. Lancet Oncology, The, 2019, 20, e1.	10.7	1
113	Missed opportunities and challenges for surgical breast cancer research in the era of personalized cancer treatment. European Journal of Surgical Oncology, 2020, 46, 501-503.	1.0	1
114	Abstract 3746: PI3K inhibition sensitizes to PARP inhibitors in patient-derived xenograft models of triple negative breast cancer. , 2012, , .		1
115	P3-07-11: Multicenter Comparative Study between One-Step Nucleic Acid Amplification (OSNA) Whole Node Assay and Standard Frozen Section Histology: Intraoperative Molecular Assay for Sentinel Lymph Node Metastases in Early Breast Cancer Can Avoid a Second Surgery.. Cancer Research, 2011, 71, P3-07-11-P3-07-11.	0.9	1
116	Use of genome typing in breast cancer. Journal of Surgical Oncology, 2009, 99, 3-4.	1.7	0
117	E9. Oncoplastic Surgery: increasing surgical options for breast cancer patients. European Journal of Cancer, 2012, 48, S20-S21.	2.8	0
118	306: Chemotherapy sensitizes p95HER2-positive breast cancers to trastuzumab. European Journal of Cancer, 2014, 50, S72-S73.	2.8	0
119	Positive sentinel lymph node: the evolution of axillary surgery and intraoperative assessment of sentinel lymph nodes. Breast Cancer Management, 2014, 3, 369-376.	0.2	0
120	Lack of RAD51 foci formation enables the identification of PARP inhibitor sensitive breast tumors. European Journal of Cancer, 2016, 69, S122-S123.	2.8	0
121	Breast and axillary conservative surgery after neoadjuvant treatment in HER 2 positive breast cancer patients: The time is now. European Journal of Cancer, 2018, 92, S13-S14.	2.8	0
122	Routine nodal radiation therapy may be avoided in Z0011 eligible breast cancer patients. It is time to reduce morbidity from axillary treatment. European Journal of Cancer, 2018, 92, S59.	2.8	0
123	Axillary Reverse Mapping: ARM. , 2018, , 303-312.		0
124	Variations in the opinion of breast surgeons and radiation oncologist regarding indications for radiation therapy after NSM: The need for prospective studies. European Journal of Surgical Oncology, 2018, 44, 3-4.	1.0	0
125	Changes in Ki 67 expression after neoadjuvant therapy in HER2 positive breast cancer patients treated with trastuzumab and pertuzumab are independent predictors of response and prognosis. European Journal of Cancer, 2018, 92, S98.	2.8	0
126	Skin sparing mastectomy and immediate breast reconstruction: more indications with no increased in recurrences in breast cancer patients.. , 2009, , .		0

#	ARTICLE	IF	CITATIONS
127	Abstract P5-14-14: Benefit of Metallic Marker for Tumor Localization in Breast Cancer Patients Treated with Breast Conservative Surgery after Neoadjuvant Treatment. Comparative Study of Tumor Localization Markers. , 2010, , .		0
128	Abstract P1-01-05: Clinical Significance of Tumor Burden in the Sentinel Nodes after Neoadjuvant Therapy Differs from Sentinel Nodes in the Adjuvant Setting and This May Influence the Management of the Axilla. , 2010, , .		0
129	P3-07-45: Role of SPECT-CT in Detecting Sentinel Lymph Nodes in Patients with Ipsilateral Breast Cancer Recurrence and Previous Axillary Lymph Node Dissection.. , 2011, , .		0
130	P3-07-21: Sentinel Lymph Node Metastasis Are More Likely To Develop in Triple Positive Breast Cancer Patients without Compromising Disease Free Survival.. , 2011, , .		0
131	Abstract P2-01-17: Total tumoral load as a prediction tool of non-sentinel node metastases in patients with early breast cancer and positive sentinel lymph node assessed by OSNA. , 2015, , .		0
132	Abstract P3-01-04: Improved sentinel lymph node detection with the use of superparamagnetic iron oxide tracer after neoadjuvant treatment in breast cancer patients. , 2016, , .		0
133	Analysis of total tumor load of sentinel lymph node as a prognostic factor in patients with early breast cancer.. Journal of Clinical Oncology, 2016, 34, 1042-1042.	1.6	0
134	Abstract P3-13-23: Predicting residual disease in breast conservative surgery after neoadjuvant treatments in breast cancer patients using the margin index tool. , 2017, , .		0
135	Abstract P6-19-01: Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. , 2019, , .		0
136	Abstract P3-03-15: Patient reported outcomes in women undergoing sentinel lymph node biopsy in the SUNRISE randomized trial evaluating different doses of superparamagnetic iron oxide. , 2019, , .		0
137	Abstract P4-10-03: The genomic landscape of male breast cancers using the oncomine comprehensive assay for actionable mutations. , 2020, , .		0
138	ASO Visual Abstract: Health-Related Quality of Life After Nipple-Sparing Mastectomy:ÂResults from the INSPIRE Registry. Annals of Surgical Oncology, 2022, 29, 1735-1736.	1.5	0